Ismael Rodriguez Rivera, MD, Medical Oncologist and Clinical Investigator from NEXT Oncology, has conducted a groundbreaking study on a novel therapeutic approach for patients with advanced or metastatic solid tumors. Read the full article, and see the video on the OncologyTube website. iFrame is not supported!
ZielBio to Present Interim Findings from its Phase 1/2
ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases, will present the first set of clinical data from its lead asset, ZB131, directed against cancer-specific plectin (CSP), during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. In an interim analysis (n=32) of the Phase 1/2 trial, ZB131 demonstrated a favorable safety and tolerability …
Machine Learning in the Diagnosis of Gastric Cancer and Pulmonary Nodule Workup
Machine learning algorithms are increasingly being applied across different areas of medicine and oncology to analyze large data sets and draw conclusions that may otherwise escape the human eye. Indeed, artificial intelligence is slowly eliminating the boundaries imposed by the limited computational ability of humans to the benefit of both clinicians and their patients. At the 2023 ASCO Annual Meeting, …
Worldwide Clinical Trials Expands Site Alliance Collaboration to Support Oncology Trials
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–In response to the growing and ever-changing clinical research landscape and the need to bring innovative treatments to patients faster, Worldwide Clinical Trials (Worldwide), a leading global, full-service contract research organization (CRO), has expanded its Site Alliance Collaboration with new partners across the United States and Europe. Additions include new relationships with NEXT Oncology in Spain and the pan-European Pratia Research Platform, along …
Drug Development in Gastric Cancer: Are We at an Inflection Point?
Gastric cancer drug development has long been thwarted by the challenges of identifying effective targets and developing drugs against the backdrop of the cancer’s inherent tumor heterogeneity.1 Recently, however, advances in our understanding of the molecular underpinnings of gastric cancer and the discovery of actionable biomarkers have led to substantial progress in drug development, leading to improved survival in gastric cancer. …
ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor
SAN DIEGO and SHANGHAI, May 5, 2023 /PRNewswire/ — ABM Therapeutics, an innovative clinical-stage biopharmaceutical company, with an emphasis on developing drugs with high blood–brain barrier (BBB) penetration for CNS diseases including brain metastases, today announced that the first patient was successfully dosed with ABM-168 in the United States. MEK (mitogen-activated protein kinase kinase), a key kinase of the MAPK pathway, is frequently activated in …
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma
SAN FRANCISCO and SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a clinical-stage precision oncology company, today announced positive monotherapy dose escalation data for its investigational, highly selective and potent pan-RAF inhibitor, exarafenib, from Part A1 of its ongoing global Phase 1 KN-8701 clinical trial. These results will be featured in an oral presentation today …
MatTek and NEXT Oncology Announce Licensing Agreement
The Boston-based biotech company will use an inventory of patient-derived cancer cells to develop new lab-grown tumor models to accelerate and refine oncology research, and provide more targeted treatments for cancer patients. [For immediate release: Ashland, MA and San Antonio, TX, April 17, 2023] – MatTek Life Sciences and NEXT Oncology jointly announced today a licensing agreement that will have MatTek turn NEXT Oncology’s …
Phase 1 Trial of DK210 Begins Dosing Patients With EGFR+ Solid Tumors
The first patient has been dosed with DK210 in a first-in-human, phase 1 clinical trial (NCT05704985) for patients with EGFR-expressing advanced solid tumors.1 “The Diakine™ platform combines the potent anti-cancer function of interleukin-2 [IL-2] with the inflammation-controlling function of interleukin-10 and targets these cytokines to the tumor,” Alexander Spira, MD, PhD, FACP, co-director of the Virginia Cancer Specialists Research Institute, told …
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that discovers novel target-antibody pairs through its unbiased interrogation of the human immune response, today announced the formation of an advisory board, comprised of Dr. John Lambert and Dr. Anthony Tolcher, to prioritize selection of novel targets for antibody drug conjugates (ADCs) and T cell redirection (TCR) modalities. Read the …